胃肠间质瘤分子病理诊断及靶向治疗进展

Recent advances in molecular pathological diagnosis and targeted therapy of gastrointestinal stromal tumors

近年来,胃肠间质瘤(GIST)在分子标记物、基因检测、靶向治疗药物药效评估等方面的研究有诸多进展。DOG1、PKC-θ、ETV1等新的标记物的发现有助于提高GIST的检出率,同时为寻找新的靶向治疗的靶点提供了方向。目前伊马替尼作为靶向治疗一线药物对于改善GIST患者的预后有重要意义,其耐药机制及新的靶向药物的研制仍需要进一步探索研究。该文对GIST分子病理诊断及靶向治疗的研究进展进行综述。

In recent years , there are a lot of progress in these areas of gastrointestinal stromal tumor （ GIST） include molecular markers, gene detection, targeted therapy drugs efficacy assessment .Discovery of DOG1, PKC-θ, ETV1 and other new markers helps to improve the detection rate of GIST , and provide new direction for discovering special therapeutic targets .Currently imatinib as first-line drugs for targeted therapy has great significance for impro-ving the prognosis of patients with GIST , mechanisms of drug resistance and the development of new targeted drugs still need further exploration and research .In this paper , the recent advances in molecular pathological diagnosis and targeted therapy of GIST were reviewed .